NL-OMON55125已完成2 期
Study on the Safety, Tolerability and Efficacy of the Aqua Medical focal vapor ablation system, for the eradication of Barrett*s Esophagus - part 2 - The STEAM-BE study 2
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •Adult patients with Barrett esophagus and early neoplasia, with an indication
- •for endoscopic treatment
排除标准
- •Patients with prior ablation therapy or contra-indications for ablation
- •therapy. Subjects with any condition that in the opinion of the PI preclude
- •enrollment into the trial,
研究者
相似试验
招募中
Unknown
Study on the Safety, Tolerability and Efficacy of the Aqua Medical focal vapor ablation system, for the eradication of Barrett's Esophagus - part 2NL-OMON20279Aqua Medical, Inc.19
尚未招募
Unknown
Soft capsules with ozonated sunflower oil versus oral OLEOZON® in patients with GiardiosisGiardiosisRPCEC00000440ational Centre for Scientific Research (CNIC)200
尚未招募
3 期
Abexol (suspension) versus Abexol (tablets) in patients with gastrointestinal symptomsGastrointestinal symptomsSigns and Symptoms, DigestiveDigestive System DiseasesRPCEC00000372ational Centre for Scientific Research100
进行中（未招募）
1 期
Phase 2b study evaluating efficacy, safety and tolerability of study drug called NGM282 (Aldafermin) in Patients with Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisCompensated Cirrhosis Due to Nonalcoholic SteatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.1Level: LLTClassification code 10064844Term: Compensated cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2019-002341-38-FRGM Biopharmaceuticals, Inc.150
已完成
不适用
study on low back paiCTRI/2016/10/007348Dr Reddys Laboratories Pvt Ltd